DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

Clinical Trials for Brevibloc Double Strength In Plastic Container

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01114971	Labetalol and Esmolol: Vital Signs and Post Operative Pain Management	Recruiting	Cedars-Sinai Medical Center	Phase 4	This study proposes to investigate the effects of labetalol or esmolol on managing the vital signs (like blood pressure and heart rate) during surgery, on pain management, and on the later recovery after surgery. It will also assess the cost-effectiveness of Labetalol and esmolol for outpatient surgery.
NCT01179113	Esmolol Infusion During Laminectomy: Effect on Quality of Recovery	Terminated	Cedars-Sinai Medical Center	Phase 4	The purpose of this study is to evaluate the effects of esmolol, a drug which is commonly administered during surgery to help control blood pressure and heart rate, on postoperative pain levels and requirements for pain medication.
NCT01208402	Esmolol for Treatment of Perioperative Tachycardia	Terminated	Baxter Healthcare Corporation	Phase 3	The purpose of this study is to find out if Esmolol is a safe and effective alternative treatment compared to standard treatment using a long acting beta blocker drug, in controlling abnormal heart rate before, during and immediately after surgery.
NCT01208402	Esmolol for Treatment of Perioperative Tachycardia	Terminated	Duke University	Phase 3	The purpose of this study is to find out if Esmolol is a safe and effective alternative treatment compared to standard treatment using a long acting beta blocker drug, in controlling abnormal heart rate before, during and immediately after surgery.
NCT01232400	Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage	Withdrawn	University of Michigan	N/A	The purpose of this study is to evaluate the clinical effect of esmolol treatment on cardiac function and electrophysiology; to assess the effects of esmolol treatment on serum adrenergic and cardiac biomarkers; to explore the safety of esmolol treatment shortly after subarachnoid hemorrhage (SAH). Patients will be followed for a maximum of 1 month after the index SAH. The primary outcome will be change in systolic function - ejection fraction by Simpson's rule (baseline versus Day 7 +/- 2 after SAH).
Trial ID	Title	Status	Sponsor	Phase	Summary